Efficacy and safety of a new ranibizumab biosimilar CKD-701 using a pro re nata treatment regimen in neovascular age-related macular degeneration: A phase 3 randomized clinical trial

• Chang Ki Yoon ,

  Contributed equally to this work with: Chang Ki Yoon, Jaeryung Oh

  Roles Data curation, Formal analysis, Writing – original draft

  Affiliation Department of Ophthalmology, Seoul National University College of Medicine, Seoul, South Korea

  ⨯
• Jaeryung Oh ,

  Contributed equally to this work with: Chang Ki Yoon, Jaeryung Oh

  Roles Formal analysis, Methodology, Project administration, Supervision, Writing – original draft

  Affiliation Department of Ophthalmology, Korea University College of Medicine, Seoul, South Korea

  ⨯
• Kunho Bae,

  Roles Writing – original draft

  Affiliation Department of Ophthalmology, Seoul National University College of Medicine, Seoul, South Korea

  ⨯
• Un Chul Park,

  Roles Project administration, Supervision

  Affiliation Department of Ophthalmology, Seoul National University College of Medicine, Seoul, South Korea

  ⨯
• Kyung-Sang Yu,

  Roles Methodology, Writing – review & editing

  Affiliation Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, South Korea

  ⨯
• Hyeong Gon Yu

  Roles Conceptualization, Methodology, Supervision, Validation

  * E-mail: hgonyu@snu.ac.kr

  Affiliation Department of Ophthalmology, Seoul National University College of Medicine, Seoul, South Korea

  https://orcid.org/0000-0002-1795-202X

  ⨯